BAG3 and myofibrillar myopathy: Two patients (patient 1 and 2) participated in an experimental trial (approved by the local ethical committee) with metformin (2 g per day), which has shown potential benefits in animal models of BAG3-related myofibrillar myopathy (Ruparelia et al., 2021), though its efficacy in humans remains uncertain.